Anastrozole Receives FDA Priority Review for Early Breast Cancer Indication

Publication
Article
OncologyONCOLOGY Vol 16 No 5
Volume 16
Issue 5

The US Food and Drug Administration (FDA) has granted a 6-month priority review status to the supplemental new drug application filed by the AstraZeneca corporation for the use of anastrozole (Arimidex) in the adjuvant treatment of early breast cancer in postmenopausal women.

The US Food and Drug Administration (FDA)has granted a 6-month priority review status to the supplemental new drugapplication filed by the AstraZeneca corporation for the use of anastrozole(Arimidex) in the adjuvant treatment of early breast cancer in postmenopausalwomen. Priority review status is granted for new drugs or indications thatrepresent a significant improvement in efficacy or safety over existingtreatments.

"AstraZeneca is committed to constantly expanding thetreatment options breast cancer patients have at their disposal to fight thisdisease," said Gerard T. Kennealey, MD, vice president of clinicalresearch, oncology, for AstraZeneca. "The FDA’s granting of priorityreview status for Arimidex as an early breast cancer treatment is an importantmilestone in the history of breast cancer treatment."

ATAC Trial

Priority review status for anastrozole was based on data fromthe ATAC study (Arimidex and Tamoxifen, Alone or in Combination) conducted inmore than 9,300 postmenopausal women with early breast cancer. Early resultsfrom that study showed that anastrozole reduced the risk of disease recurrenceby 17% over tamoxifen as well as the risk of contralateral breast cancer by 58%over tamoxifen.

Current Indications

Anastrozole is currently approved for first-line treatment ofpostmenopausal women with hormone receptor-positive or hormone receptor-unknownlocally advanced or metastatic breast cancer and also for the treatment ofadvanced breast cancer in postmenopausal women with disease progressionfollowing tamoxifen therapy. Common side effects seen in clinical trials haveincluded hot flashes, nausea, asthenia, back and bone pain, and increased cough.Joint pain and stiffness have also been reported.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content